Drug Profile


Alternative Names: Aflamin; Airtal; Airtal Difucrem; Barcan; Biofenac; Bristaflam; Cartrex; Falcol; Falcol Difucrem; Gerbin; Gerbin Difucrem; PR 82/3; Preservex; YT 919

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.; ASKA Pharmaceutical; Daewoong Pharmaceutical; Farma Lepori; Gedeon Richter; Pfizer; Probios; Roche; Sanofi; Sanofi Winthrop; Sintesa; UCB; Yakult Honsha
  • Class Antirheumatics; Esters; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatic disorders; Rheumatoid arthritis
  • Discontinued Inflammation; Pain

Most Recent Events

  • 03 Oct 2005 Grelan Pharmaceutical has merged with Teikoku Hormone to form ASKA Pharmaceutical
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top